Literature DB >> 20454827

Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA.

S Naggie1, J Frederick, B C Pien, B A Miller, D T Provenzale, K C Goldberg, C W Woods.   

Abstract

BACKGROUND: There is increasing recognition of the importance of community-associated Clostridium difficile infection (CA-CDI) despite little being known about its epidemiology.
METHODS: We performed routine, active laboratory surveillance for CDI at the Durham Veterans Affairs Medical Center between January and December 2005 and extracted data from the electronic medical record for this investigation. Bivariable analyses were performed using the chi-square test, and continuous variables were compared using two sample t test and Wilcoxon rank sums.
RESULTS: We identified 108 CDI cases during the study period; 38 (35%) had onset of disease in the community and, of these, 31 (82%) met the definition for CA-CDI. A comparison of CA- versus healthcare facility-associated (HCFA)-CDI revealed that CA-CDI patients were younger (median age 58 vs. 69 years, respectively; p = 0.01), with the majority being <65 years, but had similar co-morbidities to HCFA-CDI patients. CA-CDI patients were reportedly exposed less frequently to an antimicrobial or a proton pump inhibitor than HCFA-CDI patients, while the latter showed a trend towards a higher 60-day all-cause mortality (3 vs. 17%, respectively; p = 0.06).
CONCLUSIONS: CA-CDI is the primary reason for community-onset CDI in our community. Compared to patients with HCFA-CDI, those with CA-CDI were younger, had fewer reported exposures to antimicrobials or PPIs, and had lower mortality. Further study is needed to identify unrecognized risk factors of CDI in the community.

Entities:  

Mesh:

Year:  2010        PMID: 20454827     DOI: 10.1007/s15010-010-0025-0

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

2.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

4.  Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital.

Authors:  M F Price; T Dao-Tran; K W Garey; G Graham; L O Gentry; L Dhungana; H L Dupont
Journal:  J Hosp Infect       Date:  2006-12-04       Impact factor: 3.926

5.  A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.

Authors:  Sophia V Kazakova; Kim Ware; Brittany Baughman; Oleg Bilukha; Anne Paradis; Stephen Sears; Angie Thompson; Bette Jensen; Lois Wiggs; Jemelie Bessette; James Martin; Judy Clukey; Kathleen Gensheimer; George Killgore; L Clifford McDonald
Journal:  Arch Intern Med       Date:  2006 Dec 11-25

6.  Surveillance for community-associated Clostridium difficile--Connecticut, 2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-04-04       Impact factor: 17.586

7.  Epidemiology of community-acquired Clostridium difficile-associated diarrhea.

Authors:  L R Hirschhorn; Y Trnka; A Onderdonk; M L Lee; R Platt
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

8.  Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital.

Authors:  Heidi T Chang; Dorota Krezolek; Stuart Johnson; Jorge P Parada; Charlesnika T Evans; Dale N Gerding
Journal:  Infect Control Hosp Epidemiol       Date:  2007-06-14       Impact factor: 3.254

9.  Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005.

Authors:  Preeta K Kutty; Stephen R Benoit; Christopher W Woods; Arlene C Sena; Susanna Naggie; Joyce Frederick; John Engemann; Sharon Evans; Brian C Pien; Shailendra N Banerjee; Jeffery Engel; L Clifford McDonald
Journal:  Infect Control Hosp Epidemiol       Date:  2008-03       Impact factor: 3.254

10.  Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.

Authors:  Preeta K Kutty; Christopher W Woods; Arlene C Sena; Stephen R Benoit; Susanna Naggie; Joyce Frederick; Sharon Evans; Jeffery Engel; L Clifford McDonald
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

View more
  14 in total

1.  Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection.

Authors:  C A Duplessis; D You; M Johnson; A Speziale
Journal:  Infection       Date:  2011-12-08       Impact factor: 3.553

2.  Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.

Authors:  L Alcalá; E Reigadas; M Marín; A Martín; P Catalán; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-24       Impact factor: 3.267

3.  Clostridium difficile infection: monoclonal or polyclonal genesis?

Authors:  M Hell; M Permoser; G Chmelizek; J M Kern; M Maass; S Huhulescu; A Indra; F Allerberger
Journal:  Infection       Date:  2011-08-09       Impact factor: 3.553

4.  Two case reports of Clostridium difficile bacteremia, one with the epidemic NAP-1 strain.

Authors:  J Hemminger; J-M Balada-Llasat; M Raczkowski; M Buckosh; P Pancholi
Journal:  Infection       Date:  2011-04-21       Impact factor: 3.553

5.  Characterization of cases of Clostridium difficile infection (CDI) presenting at an emergency room: molecular and clinical features differentiate community-onset hospital-associated and community-associated CDI in a tertiary care hospital.

Authors:  Bo-Moon Shin; Se Jin Moon; You Sun Kim; Won Chang Shin; Hyeon Mi Yoo
Journal:  J Clin Microbiol       Date:  2011-04-06       Impact factor: 5.948

Review 6.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

7.  Community-associated Clostridium difficile infection among veterans with spinal cord injury and disorder.

Authors:  Salva N Balbale; Stuart Johnson; Stephen P Burns; Stephen M Kralovic; Barry Goldstein; Dale N Gerding; Charlesnika T Evans
Journal:  Infect Control Hosp Epidemiol       Date:  2014-03-24       Impact factor: 3.254

8.  Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study.

Authors:  Jennifer L Kuntz; Elizabeth A Chrischilles; Jane F Pendergast; Loreen A Herwaldt; Philip M Polgreen
Journal:  BMC Infect Dis       Date:  2011-07-15       Impact factor: 3.090

9.  Community-associated Clostridium difficile infections, Monroe County, New York, USA.

Authors:  Ghinwa Dumyati; Vanessa Stevens; George E Hannett; Angela D Thompson; Cherie Long; Duncan Maccannell; Brandi Limbago
Journal:  Emerg Infect Dis       Date:  2012-03       Impact factor: 6.883

10.  Outpatient healthcare settings and transmission of Clostridium difficile.

Authors:  Lucy A Jury; Brett Sitzlar; Sirisha Kundrapu; Jennifer L Cadnum; Kim M Summers; Christine P Muganda; Abhishek Deshpande; Ajay K Sethi; Curtis J Donskey
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.